Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Clinical Rheumatology|July 4, 2021
Real-world data on MTX tolerance with regimens used in children versus adultsUmmusen Kaya Akca, Bayram Farisogullari, Gozde Kubra Yardimci, et al.
BMJ Open|May 3, 2024
Factors influencing the outcomes of non-pharmacological interventions for managing fatigue across the lifespan of people living with musculoskeletal (MSK) conditions: a scoping review protocolKatie Fishpool, George Young, Coziana Ciurtin, et al.
RMD Open|October 24, 2025
Instruments for measuring fatigue in people with rheumatic and musculoskeletal diseases: a systematic review of measurement propertiesEduardo José Ferreira Santos, Bayram Farisogullari, Katie Fishpool, et al.
RMD Open|January 6, 2026
Prevalence and anatomical distribution of MRI lesions in axSpA and differences between patients with and without peripheral involvement: results from the ASAS classification cohortBayram Farisogullari, Stephanie Wichuk, Xenofon Baraliakos, et al.
Clinical and Experimental Rheumatology|March 29, 2022
Comprehensive assessment and outcomes of patients with chronic periaortitisGozde Kubra Yardimci, Selin Ardali Düzgün, Bayram Farisogullari, et al.
Immunity, Inflammation and Disease|December 22, 2023
Extended autoantibody panel in Turkish patients with early-stage systemic sclerosis: Coexpressions and their influences on clinical phenotypesDuygu Temiz Karadağ, Andac Komac, Yesim Erez, et al.
Rheumatology and Therapy|June 9, 2023
Hematologic Malignancy Risk in Inflammatory Arthritis Patients Treated with TNF Inhibitors: The Real-Life Data from the HUR-BIO RegistryEmine Duran, Zeynep Ozge Ozturk, Emre Bilgin, et al.
Rheumatology Advances in Practice|April 2, 2026
Real-world experience with Janus kinase inhibitors in rheumatoid and psoriatic arthritis: retention and discontinuation factors in a UK six-centre cohortJoseph Nathan, Bayram Farisogullari, Nicholas Jones, et al.
Clinical and Experimental Rheumatology|August 31, 2023
Tocilizumab as a first line biologic agent in rheumatoid arthritis patients with inadequate response to disease-modifying anti-rheumatic drugs: real life experience from the TReasure RegistryOmer Karadag, Bayram Farisogullari, Burcu Yagiz, et al.
Annals of the Rheumatic Diseases|May 30, 2024
Factors associated with disease flare following SARS-CoV-2 vaccination in people with inflammatory rheumatic and musculoskeletal diseases: results from the physician-reported EULAR Coronavirus Vaccine (COVAX) RegistryBayram Farisogullari, Saskia Lawson-Tovey, Kimme L Hyrich, et al.
Pageof 3